MPFRF
Q4 2026 EPS Estimate
$0.07
Oct 29, 2026 · Reports before open
Revenue Estimate
$7.67B
FY2026E EPS$0.42
FY2027E EPS$0.43

No analyst ratings available

No analyst price targets available for MPFRF

Analyst coverage may not be available for this symbol

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+3.30%
EPS+2.85%
FY2028
Rev+3.42%
EPS+3.65%
FY2029
Rev+6.45%
EPS+5.23%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$30.01B$31.00B$32.06B$34.13B
Low$29.91B$26.10B$29.50B$31.41B
High$30.14B$32.78B$33.04B$35.17B
EBITDA Avg$1.88B$1.91B$1.97B$2.06B
Low$1.71B$1.74B$1.79B$1.87B
High$1.94B$1.98B$2.04B$2.13B
EBIT Avg$1.62B$1.66B$1.72B$1.81B
Low$1.45B$1.49B$1.55B$1.63B
High$1.68B$1.73B$1.79B$1.89B
Net Income Avg$1.28B$1.31B$1.36B$1.43B
Low$1.15B$1.18B$1.22B$1.29B
High$1.33B$1.37B$1.42B$1.49B
EPS Avg$0.42$0.43$0.44$0.47
Low$0.37$0.38$0.40$0.42
High$0.43$0.45$0.46$0.49
Analysts (Rev / EPS)3 / 34 / 21 / 32 / 3
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$5.42B$4.60B$4.50B$4.69B$4.74B$4.16B$5.14B$6.81B
Low$5.42B$4.60B$4.50B$4.69B$4.74B$4.16B$5.14B$6.81B
High$5.42B$4.60B$4.50B$4.69B$4.74B$4.16B$5.14B$6.81B
EBITDA Avg$781M$668M$754M$679M$603M$571M$567M$1.21B
Low$781M$668M$754M$679M$603M$571M$567M$1.21B
High$781M$668M$754M$679M$603M$571M$567M$1.21B
EBIT Avg$242M$154M$264M$212M$158M$147M$161M$825M
Low$242M$154M$264M$212M$158M$147M$161M$825M
High$242M$154M$264M$212M$158M$147M$161M$825M
Net Income Avg$191M$122M$208M$168M$124M$116M$127M$651M
Low$191M$122M$208M$168M$124M$116M$127M$651M
High$191M$122M$208M$168M$124M$116M$127M$651M
EPS Avg$0.06$0.04$0.07$0.05$0.04$0.04$0.04$0.21
Low$0.06$0.04$0.07$0.05$0.04$0.04$0.04$0.21
High$0.06$0.04$0.07$0.05$0.04$0.04$0.04$0.21
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

No recent analyst actions

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.